Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 265

1.

High-Plex Predictive Marker Discovery for Melanoma Immunotherapy-Treated Patients Using Digital Spatial Profiling.

Toki MI, Merritt CR, Wong PF, Smithy JW, Kluger HM, Syrigos KN, Ong GT, Warren SE, Beechem JM, Rimm DL.

Clin Cancer Res. 2019 Sep 15;25(18):5503-5512. doi: 10.1158/1078-0432.CCR-19-0104. Epub 2019 Jun 12.

PMID:
31189645
2.

A rare case of bone marrow BCG-itis responding to second-line anti-tuberculosis treatment.

Anagnostopoulos I, Lagou S, Papatheodoridi M, Marinos L, Karakatsanis S, Syrigos KN.

Int J Tuberc Lung Dis. 2019 Jan 1;23(1):119-120. doi: 10.5588/ijtld.18.0576. No abstract available.

PMID:
30674384
3.

PET/CT and brain MRI role in staging NSCLC: prospective assessment of the accuracy, reliability and cost-effectiveness.

Gkogkozotou VI, Gkiozos IC, Charpidou AG, Kotteas EA, Boura PG, Tsagouli SN, Syrigos KN.

Lung Cancer Manag. 2018 May 31;7(2):LMT02. doi: 10.2217/lmt-2018-0008. eCollection 2018 Jun.

4.

Hypoplastic thrombocytopenia and platelet transfusion: therapeutic goals.

Karakatsanis SJ, Papadatos SS, Syrigos KN.

Hosp Pract (1995). 2019 Feb;47(1):16-23. doi: 10.1080/21548331.2019.1546530. Epub 2018 Nov 14. Review.

PMID:
30409035
5.

Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations.

Toki MI, Mani N, Smithy JW, Liu Y, Altan M, Wasserman B, Tuktamyshov R, Schalper K, Syrigos KN, Rimm DL.

J Thorac Oncol. 2018 Dec;13(12):1884-1896. doi: 10.1016/j.jtho.2018.09.012. Epub 2018 Sep 26.

PMID:
30267840
6.

Phase II study of panitumumab combined with capecitabine and oxaliplatin as first-line treatment in metastatic colorectal cancer patients: clinical results including extended tumor genotyping.

Papaxoinis G, Kotoula V, Giannoulatou E, Koliou GA, Karavasilis V, Lakis S, Koureas A, Bobos M, Chalaralambous E, Daskalaki E, Chatzopoulos K, Tsironis G, Pazarli E, Chrisafi S, Samantas E, Kaklamanos IG, Varthalitis I, Konstantara A, Syrigos KN, Pentheroudakis G, Pectasides D, Fountzilas G.

Med Oncol. 2018 May 31;35(7):101. doi: 10.1007/s12032-018-1160-1.

PMID:
29855806
7.

Epidemiological Characteristics, EGFR Status and Management Patterns of Advanced Non-small Cell Lung Cancer Patients: The Greek REASON Observational Registry Study.

Syrigos KN, Georgoulias V, Zarogoulidis K, Makrantonakis P, Charpidou A, Christodoulou C.

Anticancer Res. 2018 Jun;38(6):3735-3744. doi: 10.21873/anticanres.12654.

PMID:
29848736
8.

Sarcoidosis-Like Reactions Induced by Checkpoint Inhibitors.

Gkiozos I, Kopitopoulou A, Kalkanis A, Vamvakaris IN, Judson MA, Syrigos KN.

J Thorac Oncol. 2018 Aug;13(8):1076-1082. doi: 10.1016/j.jtho.2018.04.031. Epub 2018 May 12. Review.

9.

Lung Metastasis From Fibrosarcomatous Dermatofibrosarcoma Protuberans of the Vulva: A Rare Case Report.

Vathiotis IA, Psichogiou E, Syrigos KN, Kotteas EA.

J Low Genit Tract Dis. 2018 Jan;22(1):85-87. doi: 10.1097/LGT.0000000000000360. No abstract available.

PMID:
29271862
10.

Thermal ablation may improve outcomes in patients with colorectal liver metastasis: a case-control study.

Poulou LS, Thanos L, Ziakas PD, Merikas E, Achimastos A, Gennatas C, Syrigos KN.

J BUON. 2017 May-Jun;22(3):673-678.

11.

Lapatinib with whole brain radiotherapy in patients with brain metastases from breast and non-small cell lung cancer: a phase II study of the Hellenic Cooperative Oncology Group (HeCOG).

Christodoulou C, Kalogera-Fountzila A, Karavasilis V, Kouvatseas G, Papandreou CN, Samantas E, Varaki K, Papadopoulos G, Bobos M, Rallis G, Razis E, Goudopoulou A, Kalogeras KT, Syrigos KN, Fountzilas G.

J Neurooncol. 2017 Sep;134(2):443-451. doi: 10.1007/s11060-017-2548-z. Epub 2017 Jul 7.

PMID:
28687923
12.

Optimizing diet and nutrition for cancer survivors: A review.

Mourouti N, Panagiotakos DB, Kotteas EA, Syrigos KN.

Maturitas. 2017 Nov;105:33-36. doi: 10.1016/j.maturitas.2017.05.012. Epub 2017 May 19. Review.

PMID:
28545906
13.

Proof of the quantitative potential of immunofluorescence by mass spectrometry.

Toki MI, Cecchi F, Hembrough T, Syrigos KN, Rimm DL.

Lab Invest. 2017 Mar;97(3):329-334. doi: 10.1038/labinvest.2016.148. Epub 2017 Jan 16.

14.

The use of novel oral anticoagulants in cancer patients with venous thromboembolism.

Karakatsanis SJ, Roumpi A, Syrigos KN.

Semin Oncol. 2016 Dec;43(6):655-665. doi: 10.1053/j.seminoncol.2016.11.009. Epub 2016 Nov 18. Review.

PMID:
28061983
15.

EGFR-GRB2 Protein Colocalization Is a Prognostic Factor Unrelated to Overall EGFR Expression or EGFR Mutation in Lung Adenocarcinoma.

Toki MI, Carvajal-Hausdorf DE, Altan M, McLaughlin J, Henick B, Schalper KA, Syrigos KN, Rimm DL.

J Thorac Oncol. 2016 Nov;11(11):1901-1911. doi: 10.1016/j.jtho.2016.06.025. Epub 2016 Jul 20.

16.

Circulating Biomarkers in Non-Small-Cell Lung Cancer: Current Status and Future Challenges.

Matikas A, Syrigos KN, Agelaki S.

Clin Lung Cancer. 2016 Nov;17(6):507-516. doi: 10.1016/j.cllc.2016.05.021. Epub 2016 Jun 8. Review.

PMID:
27373516
17.

Targeting Neovasculature with Multitargeted Antiangiogenesis Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer.

Skouras VS, Maragkos C, Grapsa D, Syrigos KN.

BioDrugs. 2016 Oct;30(5):421-439. Review.

PMID:
27670779
18.

The safety and efficacy of Onivyde (irinotecan liposome injection) for the treatment of metastatic pancreatic cancer following gemcitabine-based therapy.

Passero FC Jr, Grapsa D, Syrigos KN, Saif MW.

Expert Rev Anticancer Ther. 2016 Jul;16(7):697-703. doi: 10.1080/14737140.2016.1192471. Epub 2016 Jun 3. Review.

PMID:
27219482
19.

A Novel Technique to Treat Air Leak Following Lobectomy: Intrapleural Infusion of Plasma.

Konstantinou F, Potaris K, Syrigos KN, Tsipas P, Karagkiouzis G, Konstantinou M.

Med Sci Monit. 2016 Apr 15;22:1258-64.

20.

Profile of capecitabine/temozolomide combination in the treatment of well-differentiated neuroendocrine tumors.

Kotteas EA, Syrigos KN, Saif MW.

Onco Targets Ther. 2016 Feb 9;9:699-704. doi: 10.2147/OTT.S72155. eCollection 2016. Review.

21.

Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy.

Pérol M, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T, Park K, Kowalyszyn RD, Pikiel J, Lewanski CR, Thomas M, Dakhil S, Kim JH, Karaseva N, Yurasov S, Zimmermann A, Lee P, Carter GC, Reck M, Cappuzzo F, Garon EB.

Lung Cancer. 2016 Mar;93:95-103. doi: 10.1016/j.lungcan.2016.01.007. Epub 2016 Jan 19.

PMID:
26898621
22.

Tumour-induced neoneurogenesis and perineural tumour growth: a mathematical approach.

Lolas G, Bianchi A, Syrigos KN.

Sci Rep. 2016 Feb 10;6:20684. doi: 10.1038/srep20684.

23.

Venous Thromboembolism in Patients Diagnosed With Lung Cancer.

Salla E, Dimakakos EP, Tsagkouli S, Giozos I, Charpidou A, Kainis E, Syrigos KN.

Angiology. 2016 Sep;67(8):709-24. doi: 10.1177/0003319715614945. Epub 2015 Nov 9. Review.

PMID:
26553057
24.

Cabazitaxel Versus Topotecan in Patients with Small-Cell Lung Cancer with Progressive Disease During or After First-Line Platinum-Based Chemotherapy.

Evans TL, Cho BC, Udud K, Fischer JR, Shepherd FA, Martinez P, Ramlau R, Syrigos KN, Shen L, Chadjaa M, Wolf M.

J Thorac Oncol. 2015 Aug;10(8):1221-8. doi: 10.1097/JTO.0000000000000588.

25.

3-BrPA eliminates human bladder cancer cells with highly oncogenic signatures via engagement of specific death programs and perturbation of multiple signaling and metabolic determinants.

Konstantakou EG, Voutsinas GE, Velentzas AD, Basogianni AS, Paronis E, Balafas E, Kostomitsopoulos N, Syrigos KN, Anastasiadou E, Stravopodis DJ.

Mol Cancer. 2015 Jul 22;14:135. doi: 10.1186/s12943-015-0399-9.

26.

Immune response gene expression in colorectal cancer carries distinct prognostic implications according to tissue, stage and site: a prospective retrospective translational study in the context of a hellenic cooperative oncology group randomised trial.

Pentheroudakis G, Raptou G, Kotoula V, Wirtz RM, Vrettou E, Karavasilis V, Gourgioti G, Gakou C, Syrigos KN, Bournakis E, Rallis G, Varthalitis I, Galani E, Lazaridis G, Papaxoinis G, Pectasides D, Aravantinos G, Makatsoris T, Kalogeras KT, Fountzilas G.

PLoS One. 2015 May 13;10(5):e0124612. doi: 10.1371/journal.pone.0124612. eCollection 2015.

27.

Percentage Change in Plasma Cytokeratin 18 Is Associated with Clinical Outcomes in Patients Receiving Pemetrexed and Carboplatin for the Adenocarcinoma Subtype of NSCLC.

Strimpakos AS, Banerji U, Thavasu P, Tsilimagou A, Psyrri A, Syrigos KN.

Oncology. 2015;89(1):53-9. doi: 10.1159/000371711. Epub 2015 Feb 28.

PMID:
25766505
28.

Objective measurement and clinical significance of TILs in non-small cell lung cancer.

Schalper KA, Brown J, Carvajal-Hausdorf D, McLaughlin J, Velcheti V, Syrigos KN, Herbst RS, Rimm DL.

J Natl Cancer Inst. 2015 Feb 3;107(3). pii: dju435. doi: 10.1093/jnci/dju435. Print 2015 Mar.

29.

The role of glutamine supplementation in thoracic and upper aerodigestive malignancies.

Papanikolopoulou A, Syrigos KN, Drakoulis N.

Nutr Cancer. 2015;67(2):231-7. doi: 10.1080/01635581.2015.990572. Epub 2015 Jan 28. Review.

PMID:
25629996
30.

Hypersensitivity reactions associated with oxaliplatin and their clinical management.

Toki MI, Saif MW, Syrigos KN.

Expert Opin Drug Saf. 2014 Nov;13(11):1545-54. doi: 10.1517/14740338.2014.963551. Epub 2014 Oct 11. Review.

PMID:
25307143
31.

Docetaxel and intermittent erlotinib in patients with metastatic Non-Small Cell Lung Cancer; a phase II study from the Hellenic Cooperative Oncology Group.

Karavasilis V, Kosmidis P, Syrigos KN, Mavropoulou P, Dimopoulos MA, Kotoula V, Pectasides D, Boukovinas I, Klouvas G, Kalogera-Fountzila A, Papandreou CN, Fountzilas G, Briasoulis E.

Anticancer Res. 2014 Oct;34(10):5649-55.

PMID:
25275069
32.

MET gene copy number predicts worse overall survival in patients with non-small cell lung cancer (NSCLC); a systematic review and meta-analysis.

Dimou A, Non L, Chae YK, Tester WJ, Syrigos KN.

PLoS One. 2014 Sep 18;9(9):e107677. doi: 10.1371/journal.pone.0107677. eCollection 2014. Review.

33.

The intercellular cell adhesion molecule-1 (icam-1) in lung cancer: implications for disease progression and prognosis.

Kotteas EA, Boulas P, Gkiozos I, Tsagkouli S, Tsoukalas G, Syrigos KN.

Anticancer Res. 2014 Sep;34(9):4665-72. Review.

PMID:
25202042
34.

Clinical significance of smoking cessation in subjects with cancer: a 30-year review.

Florou AN, Gkiozos IC, Tsagouli SK, Souliotis KN, Syrigos KN.

Respir Care. 2014 Dec;59(12):1924-36. doi: 10.4187/respcare.02559. Epub 2014 Sep 2. Review.

35.

Pain and Anxiety versus Sense of Family Support in Lung Cancer Patients.

Lekka D, Pachi A, Tselebis A, Zafeiropoulos G, Bratis D, Evmolpidi A, Ilias I, Karkanias A, Moussas G, Tzanakis N, Syrigos KN.

Pain Res Treat. 2014;2014:312941. doi: 10.1155/2014/312941. Epub 2014 Jul 13.

36.

Maintenance therapy with capecitabine in patients with locally advanced unresectable pancreatic adenocarcinoma.

Saif MW, Ledbetter L, Kaley K, Garcon MC, Rodriguez T, Syrigos KN.

Oncol Lett. 2014 Sep;8(3):1302-1306. Epub 2014 Jun 11.

37.

Targeted agents in treatment of neuroendocrine tumors of pancreas.

Karampelas IN, Syrigos KN, Saif MW.

JOP. 2014 Jul 28;15(4):351-3. doi: 10.6092/1590-8577/2694. Review.

38.

Pharmacogenetics in pancreatic cancer.

Tourkantonis IS, Peponi E, Syrigos KN, Saif MW.

JOP. 2014 Jul 28;15(4):335-9. doi: 10.6092/1590-8577/2689.

39.

Elderly patients with pancreatic cancer.

Kougioumtzopoulou AS, Syrigos KN, Saif MW.

JOP. 2014 Jul 28;15(4):322-5. doi: 10.6092/1590-8577/2682.

40.

Quality of life in patients with pancreatic cancer.

Kiagia M, Syrigos KN, Saif MW.

JOP. 2014 Jul 28;15(4):317-8. doi: 10.6092/1590-8577/2679.

41.

Risk determination for pancreatic cancer.

Toki MI, Syrigos KN, Saif MW.

JOP. 2014 Jul 28;15(4):289-91. doi: 10.6092/1590-8577/2591.

42.

First line treatment for metastatic pancreatic adenocarcinoma: looking for the step forward.

Ramfidis VS, Psyrri A, Syrigos KN, Saif MW.

JOP. 2014 Jul 28;15(4):286-8. doi: 10.6092/1590-8577/2622.

43.

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.

Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T, Park K, Gorbunova V, Kowalyszyn RD, Pikiel J, Czyzewicz G, Orlov SV, Lewanski CR, Thomas M, Bidoli P, Dakhil S, Gans S, Kim JH, Grigorescu A, Karaseva N, Reck M, Cappuzzo F, Alexandris E, Sashegyi A, Yurasov S, Pérol M.

Lancet. 2014 Aug 23;384(9944):665-73. doi: 10.1016/S0140-6736(14)60845-X. Epub 2014 Jun 2.

PMID:
24933332
44.

Soluble E-cadherin as a diagnostic and prognostic marker in gastric carcinoma.

Tsalikidis C, Papachristou F, Pitiakoudis M, Asimakopoulos B, Trypsianis G, Bolanaki E, Syrigos KN, Simopoulos C.

Folia Med (Plovdiv). 2013 Jul-Dec;55(3-4):26-32.

PMID:
24712279
45.

Pulmonary hypertension after pneumonectomy for lung cancer.

Potaris K, Athanasiou A, Konstantinou M, Zaglavira P, Theodoridis D, Syrigos KN.

Asian Cardiovasc Thorac Ann. 2014 Nov;22(9):1072-9. doi: 10.1177/0218492314527992. Epub 2014 Mar 17.

PMID:
24637028
46.

Updates in management of ampullary carcinomas.

John PK, Kougioumtzopoulou AS, Syrigos KN, Saif MW.

JOP. 2014 Mar 10;15(2):140-3. doi: 10.6092/1590-8577/2283.

47.

Biomarkers in pancreatic neuroendocrine tumors.

Theochari MS, Syrigos KN, Saif MW.

JOP. 2014 Mar 10;15(2):138-9. doi: 10.6092/1590-8577/2321.

48.

The role of biliary drainage in patients with pancreatic adenocarcinoma.

Toki MI, Syrigos KN, Saif MW.

JOP. 2014 Mar 10;15(2):128-31. doi: 10.6092/1590-8577/2292.

49.

FOLFIRINOX: from the ACCORD study to 2014.

Oikonomopoulos GM, Syrigos KN, Skoura E, Saif MW.

JOP. 2014 Mar 10;15(2):103-5. doi: 10.6092/1590-8577/2278.

50.

Pancreatic cancer in 2014.

Kaltsas S, Syrigos KN, Saif MW.

JOP. 2014 Mar 10;15(2):84-6. doi: 10.6092/1590-8577/2403. No abstract available.

Supplemental Content

Loading ...
Support Center